BB Biotech Q1 2026 Achievements and Strategic Shifts

BB Biotech has reported a share price increase of +4.1% in CHF, +5.2% in EUR, and +3.2% in USD for Q1 2026, surpassing the Nasdaq Biotechnology Index in all three currencies. This performance comes amidst a net loss of CHF 21 million, showing a significant recovery from the CHF 241 million loss in Q1 2025. The discount to Net Asset Value (NAV) also decreased from 10.8% at the end of 2025 to 6.9% in March 2026, underscoring renewed investor confidence.

The quarter featured an active portfolio reshaping, expanding from 24 to 30 holdings. It included ventures into oncology, rare diseases, immunology, and cardiometabolic medicine. Notably, the addition of large-cap companies like Regeneron Pharmaceuticals and Gilead Sciences aims to enhance portfolio stability. Following strategic guidelines updates, the investment range target was broadened to 20–50 positions.

Additionally, the SPI Select Dividend 20 Index now includes BB Biotech, affirming its commitment to stable dividends and reflecting broader investments in biotechnology innovation.